₩125,800.00 ($93.64)

-3500.00 (-2.71%)

Weekly Expected Move ±3.9%

₩115884 ₩120842 ₩125800 ₩130758 ₩135716

KSC · Healthcare · Medical - Pharmaceuticals · Tech Score Neutral · Power 49 · ₩1.44T mcap · 5M float · 0.970% daily turnover

Revenue

$1.99T +18.5% ▲

5Y CAGR: +5.8%

Gross Profit

$536.0B +11.2% ▲

5Y CAGR: +4.0%

Operating Income

$67.8B +111.2% ▲

5Y CAGR: +6.2%

Net Income

-$4.7B +82.2% ▲

EPS (Diluted)

$-409.51 +82.2% ▲

EBITDA

$155.5B +93.5% ▲

5Y CAGR: -1.6%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$1.54T	$1.71T	$1.63T	$1.68T	$1.99T
YoY Growth	+2.2%	+11.3%	-4.9%	+3.3%	+18.5%
Cost of Revenue	$1.02T	$1.13T	$1.14T	$1.20T	$1.46T
Gross Profit	$520.6B	$581.8B	$484.6B	$481.9B	$536.0B
Gross Margin	33.9%	34.0%	29.8%	28.7%	26.9%
R&D Expenses	$146.0B	$191.3B	$173.5B	$166.2B	$0
SG&A Expenses	$169.1B	$165.1B	$134.4B	$130.1B	$0
Operating Expenses	$446.9B	$500.5B	$450.2B	$449.8B	$468.2B
Operating Income	$73.7B	$81.3B	$34.4B	$32.1B	$67.8B
Operating Margin	4.8%	4.7%	2.1%	1.9%	3.4%
Interest Expense	$12.5B	$18.4B	$28.5B	$40.4B	$50.3B
Income Before Tax	$172.6B	$85.7B	-$27.1B	-$41.1B	-$35.3B
Tax Expense	$35.6B	$16.3B	-$7.3B	$1.5B	-$5.6B
Net Income	$123.2B	$65.5B	-$26.6B	-$26.3B	-$4.7B
Net Margin	8.0%	3.8%	-1.6%	-1.6%	-0.2%
EPS (Diluted)	$10795.00	$5734.87	$-2333.42	$-2302.62	$-409.51
EBITDA	$159.0B	$187.0B	$109.8B	$80.4B	$155.5B
Shares Outstanding	11M	11M	11M	11M	11M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$464.9B	$440.9B	$383.8B	$500.3B	$609.5B	$497.8B	$435.5B	$421.2B
Cost of Revenue	$319.4B	$319.3B	$271.0B	$345.1B	$463.6B	$375.6B	$317.3B	$311.6B
Gross Profit	$145.5B	$121.5B	$112.7B	$155.2B	$145.9B	$122.2B	$118.2B	$109.5B
Gross Margin	31.3%	27.6%	29.4%	31.0%	23.9%	24.5%	27.1%	26.0%
R&D Expenses	$38.5B	$52.1B	$0	$38.1B	$33.5B	$44.8B	$35.3B	$0
SG&A Expenses	$30.5B	$34.7B	$31.2B	$127.8B	$42.1B	$45.8B	$36.6B	$33.8B
Operating Expenses	$101.7B	$131.6B	$104.8B	$127.8B	$116.7B	$118.9B	$106.5B	$107.8B
Operating Income	$39.6B	-$10.1B	$8.0B	$27.4B	$29.2B	$4.3B	$11.7B	$1.7B
Operating Margin	8.5%	-2.3%	2.1%	5.5%	4.8%	0.9%	2.7%	0.4%
Interest Expense	$10.7B	$11.0B	$11.6B	$12.6B	$12.8B	$13.4B	$13.3B	$11.5B
Income Before Tax	$42.9B	-$44.3B	$16.7B	$33.1B	$24.9B	-$110.1B	$28.6B	-$1.6B
Tax Expense	$7.1B	-$5.6B	-$5.6B	$454M	$6.7B	-$7.3B	$8.5B	-$2.7B
Net Income	$33.3B	-$27.3B	$29.7B	$38.0B	$15.9B	-$88.3B	$20.5B	$2.0B
Net Margin	7.2%	-6.2%	7.7%	7.6%	2.6%	-17.7%	4.7%	0.5%
EPS (Diluted)	$2915.00	$-2391.48	$2601.85	$3328.58	$1397.00	$-7736.94	$1794.00	$173.78
EBITDA	$60.2B	-$12.6B	$19.4B	$49.8B	$59.1B	$24.8B	$34.5B	$22.9B
Shares Outstanding	13M	11M	11M	11M	11M	11M	11M	6M

006280.KS KSC